Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Amazon will zum Rivalen Starlink aufschließen und Globalstar kaufen (Der Standard) +++ GLOBALSTAR Aktie +3,68%

AMICUS Aktie

 >AMICUS Aktienkurs 
12.5 EUR    (TradegateBSX)
Ask: 12.6 EUR / 4000 Stück
Bid: 12.4 EUR / 490 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
AMICUS Aktie über LYNX handeln
>AMICUS Performance
1 Woche: +0,4%
1 Monat: +2,5%
3 Monate: +2,9%
6 Monate: +88,6%
1 Jahr: +69,4%
laufendes Jahr: +2,9%
>AMICUS Aktie
Name:  AMICUS THERAPEUTICS INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US03152W1099 / A0MSMZ
Symbol/ Ticker:  AM6 (Frankfurt) / FOLD (NASDAQ)
Kürzel:  FRA:AM6, ETR:AM6, AM6:GR, NASDAQ:FOLD
Index:  -
Webseite:  https://amicusrx.com/
Profil:  Amicus Therapeutics Inc. is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. It focuses on addressing unmet medical needs in genetic disorders through proprietary technology pla..
>Volltext..
Marktkapitalisierung:  3917.66 Mio. EUR
Unternehmenswert:  4043.25 Mio. EUR
Umsatz:  548.36 Mio. EUR
EBITDA:  36.27 Mio. EUR
Nettogewinn:  -23.44 Mio. EUR
Gewinn je Aktie:  -0.08 EUR
Schulden:  382.48 Mio. EUR
Liquide Mittel:  185.04 Mio. EUR
Operativer Cashflow:  28.66 Mio. EUR
Bargeldquote:  1.23
Umsatzwachstum:  5.81%
Gewinnwachstum:  57.41%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 322.839 USD.
Suchwörter:  AMICUS
Letzte Datenerhebung:  02.04.26
>AMICUS Kennzahlen
Aktien/ Unternehmen:
Aktien: 314 Mio. St.
Frei handelbar: 98.51%
Rückkaufquote: -0.42%
Mitarbeiter: 511
Umsatz/Mitarb.: 1.07 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 0.82%
Bewertung:
KGV: -
KGV lG: 45.73
KUV: 7.07
KBV: 16.64
PEG-Ratio: -
EV/EBITDA: 111.47
Rentabilität:
Bruttomarge: 87.32%
Gewinnmarge: -4.27%
Operative Marge: 5.44%
Managementeffizenz:
Gesamtkaprendite: -3.13%
Eigenkaprendite: -11.58%
>AMICUS Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
26.03.26 - 21:30
Consumer Watchdog Files New Supreme Court Brief Challenging Unlawful Tariff "Modifications" That Raise Prices For Working Families (PR Newswire)
 
Organization Urges Court to Grant Review of Federal Circuit Decision Allowing Sevenfold Expansion of Section 301 China Tariffs with No Meaningful Limits LOS ANGELES, March 26, 2026 /PRNewswire/ -- Consumer Watchdog today filed an amicus curiae brief in the Supreme Court of the United......
12.03.26 - 16:12
Microsoft backs AI firm Anthropic in legal battle against Pentagon (The Guardian)
 
Tech company filed amicus brief in support of Anthropic's effort to overturn an aggressive Pentagon designationMicrosoft has thrown its weight behind Anthropic's legal challenge against the US Pentagon, filing a court brief in support of the AI company's effort to overturn an aggressive designation that effectively bars it from government work.In an amicus brief submitted to a federal court in San Francisco this week, Microsoft, which integrates Anthropic's AI tools into systems it provides to the US military, argued that a temporary restraining order was necessary to prevent serious disruption to suppliers whose products rely on the AI company's technology. Google, Amazon, Apple and OpenAI have also signed on to a brief in support of Anthropic. Continue reading......
11.03.26 - 17:54
Group of retired senior military officers and Microsoft file briefs supporting Anthropic in lawsuit (Sherwood)
 
Microsoft (MSFT) and a group of 22 retired senior military officers have filed amicus briefs in support of Anthropic in its lawsuit against the US government. The group of military officers includes two......
11.03.26 - 15:36
Microsoft Backs Anthropic′s Bid To Block Pentagon′s ′Supply-Chain Risk′ Label (ZeroHedge)
 
Microsoft Backs Anthropic's Bid To Block Pentagon's 'Supply-Chain Risk' Label Authored by Aldgra Fredly via The Epoch Times, Microsoft on March 10 filed an amicus brief backing Anthropic's lawsuit against the Department of War, seeking a court order to temporarily stop the Pentagon from labeling Anthropic as a supply-chain risk. Anthropic filed the suit on March 9 after the Pentagon designated it a supply chain risk to national security, a label that would hinder the Pentagon and its contractors from using Anthropic's artificial intelligence technology in their work for the U.S. military. The designation stemmed from Anthropic's rejection of the Pentagon's request for unrestricted access to its Claude models over concerns that the technology could be used for mass domestic surveillance or fully autonomous weapons. The Pentagon has denied that it planned to use Claude for such purposes. In its amicus brief filed March 10, Microsoft said it was directly affected by the Pentagon's design...
11.03.26 - 06:21
Microsoft Warns Of Costly Disruptions As It Backs Anthropic Bid To Block Department Of War Supply-Chain Risk Designation (Benzinga)
 
Microsoft backed Anthropic in court with an amicus brief seeking to block the U.S. Department of Defense from labeling the AI startup a supply-chain risk, warning the move could disrupt defense contractors relying on its technology. Importance Rank:  1 read more...
10.03.26 - 23:39
Microsoft backs Anthropic in amicus brief to halt US DOD′s ′supply-chain risk′ designation (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 22:30
Microsoft files amicus brief supporting Anthropic in Pentagon fight (The Hill)
 
The technology giant Microsoft has filed an amicus brief in Anthropic's case against the Trump administration, urging the court to temporarily block the implementation of the Pentagon labelling the Claude-maker as a supply chain risk. The filing is a significant development for Anthropic, which first filed a complaint against the administration on Monday over the......
10.03.26 - 13:06
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis (PR Newswire)
 
Genomenon's Curation and Global Distribution of Variant Data Reduces Barriers to Genetic Diagnosis ANN ARBOR, Mich., March 10, 2026 /PRNewswire/ -- Genomenon today announced a strategic sponsorship from Amicus Therapeutics to accelerate awareness, diagnosis, and research for Fabry disease.......
09.03.26 - 18:16
Texas Attorney and Hip-Hop Artists Challenge Use of Rap Lyrics in Dallas Death Penalty Sentencing (Business Wire)
 
Filing marks latest chapter in national debate over the use of rap lyrics in criminal trialsDALLAS--(BUSINESS WIRE)--#FirstAmendment--A coalition of artists, entertainers, music industry leaders and professors, including Grammy Award-winning rapper Killer Mike, Young Thug, T.I., Blackish star Anthony Anderson, and music executive Kevin Liles, have filed an amicus brief challenging the use of rap lyrics during the punishment phase of a Dallas County capital trial, arguing that prosecutors improperly relied on artistic expression to support a death sentence. In total, the brief is supported by 30 artists and scholars, and six arts organizations. Texas appellate attorney Chad Baruch of Johnston Tobey Baruch is lead counsel on the brief, with co-counsel (and amici) Professor Lucius T. Outlaw III of the Criminal Justice Clinic at Howard University School of Law. Professor Erik Nielson, one of America's leading authorities on hip-hop culture, took the lead in the effort. The brief urges the U.S. Supreme Court ...
05.03.26 - 18:03
Ford O′Brien Landy LLP Submits Sripetch v. SEC Amicus Brief (PR Newswire)
 
Filing Highlights Govil Case; Reaffirms Need for Case Precedent to Remain NEW YORK, March 5, 2026 /PRNewswire/ -- Ford O'Brien Landy LLP has filed an amicus curiae brief in the United States Supreme Court in Sripetch v. SEC, No. 25-466. In Sripetch, the Supreme Court granted certiorari to......
05.03.26 - 07:01
Insiderhandel: President and CEO verkauft Aktien von Amicus Therapeutics im Wert von 322839 USD (Insiderkauf)
 
Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2026-03-02...
27.02.26 - 10:31
BB Biotech: Gleich mehrere Zukäufe – spannende News erwartet (Der Aktionaer)
 
Im Schlussquartal 2025 hat die Schweizer Biotechgesellschaft BB Biotech einige Veränderungen am Portfolio vorgenommen. Bereits kurz nach dem Kauf wurde bei zwei Werten bereits eine Übernahme angekündigt: bei Amicus Therapeutics und Avidity Biosciences....
23.02.26 - 19:00
Amicus′ Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
 
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion....
20.02.26 - 22:12
Amicus Therapeutics Non-GAAP EPS of $0.31, revenue of $634M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.02.26 - 22:03
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates (GlobeNewswire EN)
 
2025 Total Revenue of $634M, up 17% Year-over-Year at CER...
17.02.26 - 17:00
CFTC defends its right to prediction market enforcement as states challenge platforms (CNBC)
 
CFTC Chairman Michael Selig said the agency is filing an amicus brief to assert its authority over prediction market enforcement and regulation....
16.02.26 - 22:01
What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
 
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week....
11.02.26 - 16:00
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
 
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion....
28.01.26 - 19:00
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
 
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors....
27.01.26 - 21:21
Milliman analysis: Competitive pension risk transfer cost increased from 100.1% to 100.3% during December (Business Wire)
 
Competitive bidding process saves about 3.1% of buyout costs as of December 31, 2025SEATTLE--(BUSINESS WIRE)--#PRT--Milliman, Inc., a premier global consulting and actuarial firm, today announced the latest results of its Milliman Pension Buyout Index (MPBI). During December, the estimated cost to transfer retiree pension risk to an insurer in a competitive bidding process inched up 20 basis points, from 100.1% to 100.3% of a plan's accounting liabilities (accumulated benefit obligation, or ABO). That means the estimated retiree PRT cost is now 100.3% of a plan's ABO. During the same time period, the average annuity purchase cost across all insurers in our index also increased, from 103.3% to 103.4%. The competitive bidding process is estimated to save plan sponsors about 3.1% of PRT costs as of December 31, 2025. “Earlier this month, the U.S. Department of Labor filed an amicus brief to clarify the legal context for pension risk transfers,” explained Jake Pringle, Milliman principal and co-author o...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Don′t marry, be happy. - Hera Lind
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!